ReviewMolecular oncology2016
Metastatic breast cancer: The Odyssey of personalization.
Review in Molecular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- D-Dimer Dynamics as a Prognostic and Monitoring Biomarker in Triple-Negative and Metastatic Breast Cancer: A Narrative Review.Breast cancer (Dove Medical Press) · 2026Review
- EccDNA-orientedAnnals of translational medicine · 2022Article
- External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants.Pathology oncology research : POR · 2020Article
- The genomic landscape of metastasis in treatment-naïve breast cancer models.PLoS genetics · 2020Article
- miR-140-3p inhibits breast cancer proliferation and migration by directly regulating the expression of tripartite motif 28.Oncology letters · 2019Article
- Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.Current treatment options in oncology · 2019Review
- Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications.Oncotarget · 2018Article
- MicroRNA-433 targets AKT3 and inhibits cell proliferation and viability in breast cancer.Oncology letters · 2018Article
- Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing.Journal of Cancer · 2018Review
- Exceptional Responses to Standard Therapy in a Patient with Metastatic HER2-Positive Breast Cancer.Cureus · 2017Article
- Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?International journal of molecular sciences · 2017Review
- Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.Progress in molecular biology and translational science · 2017Review
- Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.Theranostics · 2017Article
- Metastatic breast cancer: The Odyssey of personalization.Molecular oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic breast cancer is the most frequent cause of cancer death for women worldwide. In the last 15 years, a large number of new agents have entered clinical use, a result of the dramatic increase in our understanding of the molecular underpinnings of metastatic breast cancer. However, while these agents have led to better outcomes, they are also at the root cause of increasing financial pressure on healthcare systems. Moreover, decision making in an era where every year new agents are added to the therapeutic armamentarium has also become a significant challenge for medical oncologists. In the present article, we will provide an ample review on the most recent developments in the field of treatment of the different subtypes of metastatic breast cancer with a critical discussion on the slow progress made in identifying response biomarkers. New hopes in the form of ctDNA monitoring and functional imaging will be presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.